N-[2-(3-methoxy-phenyl)-ethyl]-2-phenyl-acetamide | 20341-22-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[2-(3-methoxy-phenyl)-ethyl]-2-phenyl-acetamide
• 英文别名: N-<3-Methoxy-phenaethyl>-phenylacetamid；Phenylacetyl-β-(3-methoxyphenyl)ethylamid；N-[2-(3-methoxyphenyl)ethyl]-2-phenylacetamide
• CAS: 20341-22-4
• 化学式: C₁₇H₁₉NO₂
• 分子量: 269.343
• InChiKey: BKSWQIGJBXSQQU-UHFFFAOYSA-N

物化性质

• 熔点：
  61-62 °C
• 沸点：
  491.7±38.0 °C(Predicted)
• 密度：
  1.095±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-[2-(3-methoxy-phenyl)-ethyl]-2-phenyl-acetamide 在 sodium tetrahydroborate 、 五氯化磷 、 三乙胺 作用下， 以 甲醇 、 氯仿 为溶剂， 反应 6.5h， 生成 1-benzyl-6-methoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl chloride
  参考文献：
  名称：

  苄基四氢异喹啉的光气化：一种新的berbines和berbin-8-ones合成方法

  摘要：

  据报道，通过berbin-8-ones可以合成一种新的贝宾环骨架。用光气处理1-苄基-1,2,3,4-四氢异喹啉1a-d，得到一系列新的N-氯甲酰基衍生物2a-d。在路易斯酸催化剂的存在下，这些化合物的分子内闭环以良好的产率提供了berbin-8-ones 3a-d。讨论了环化催化剂的选择。用氢化锂铝还原产物3a-d得到了小bin碱4a-d。水解小bin 4b，c生成新的3-羟基小hydroxy 4e，f。制备新的起始苄基四氢异喹啉描述图1b，c。

  DOI：

  10.1016/s0040-4020(01)83481-5
• 作为产物：
  描述：

  苯乙酸 在 氯化亚砜 、 sodium carbonate 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 4.0h， 生成 N-[2-(3-methoxy-phenyl)-ethyl]-2-phenyl-acetamide
  参考文献：
  名称：

  可见光介导的双氧氧化 1-苄基-3,4-二氢异喹啉：1-苯甲酰基异喹啉和 1-苯甲酰基-3,4-二氢异喹啉的可转换合成

  摘要：

  可见光介导的 1-苄基-3,4-二氢异喹啉 (1-BnDHIQs) 的无金属氧化，用于可切换制备多种 1-苯甲酰基异喹啉 (BzIQs) 和 1-苯甲酰基-3,4-二氢异喹啉(BzDHIQs) 是使用双氧作为氧化剂实现的。该方案为高效合成异喹啉生物碱提供了一条简便的途径。机理研究表明自由基途径和离子途径可能同时存在，这两种途径都通过共同的关键过氧化物中间体进行，产生氧化产物。

  DOI：

  10.1055/a-2160-8903

文献信息

• Copper(<scp>ii</scp>)-catalyzed and acid-promoted highly regioselective oxidation of tautomerizable C(sp³)–H bonds adjacent to 3,4-dihydroisoquinolines using air (O₂) as a clean oxidant
  作者：Yun-Gang He、Yong-Kang Huang、Qi-Qi Fan、Bo Zheng、Yong-Qiang Luo、Xing-Liang Zhu、Xiao-Xin Shi

  DOI：10.1039/d1ra05671a

  日期：——

  1-Bn-DHIQs to 1-Bz-DHIQs without concomitant excessive oxidation of 1-Bz-DHIQs to 1-Bz-IQs is very important for the syntheses of 1-Bz-DHIQ alkaloids and analogues. In this article, we developed a novel Cu(ii)-catalyzed and acid-promoted highly regioselective oxidation of tautomerizable C(sp3)-H bonds adjacent to the C-1 positions of various 1-Bn-DHIQs. It was observed that when 0.2 equiv. of Cu(OAc)2·2H2O

  一种温和、高效、环保的方法将 1-Bn-DHIQs 氧化为 1-Bz-DHIQs，且不会同时将 1-Bz-DHIQs 过度氧化为 1-Bz-IQs，这对于 1-Bz 的合成非常重要。 -DHIQ 生物碱和类似物。在本文中，我们开发了一种新型 Cu(ii) 催化和酸促进的高度区域选择性氧化，可对各种 1-Bn-DHIQ 的 C-1 位置附近的可互变 C(sp3)-H 键进行氧化。据观察，当 0.2 当量时。 Cu(OAc)2·2H2O用作催化剂，3.0当量。以AcOH为添加剂，空气（O2）为清洁氧化剂，在25℃的DMSO中，各种1-Bn-DHIQ可以有效氧化为相应的1-Bz-DHIQ。特别是，在上述反应过程中几乎没有观察到1-Bz-DHIQs过度氧化为1-Bz-IQs。此外，该方法还成功应用于生物碱canelillinoxine的首次全合成。
• [EN] TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE TETRAHYDRO-ISOQUINOLYL-ACETAMIDE DESTINES A SERVIR D'ANTAGONISTES DES RECEPTEURS D'OREXINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2004085403A1

  公开（公告）日：2004-10-07

  The invention relates to novel acetamide derivatives of formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.

  该发明涉及公式（I）的新型乙酰胺衍生物及其在制备药物组合物中作为活性成分的用途。该发明还涉及相关方面，包括制备这类化合物的方法、含有其中一个或多个这类化合物的药物组合物，特别是它们作为促进睡眠的药物受体拮抗剂的用途。
• Synthesis and Photo-oxygenation of Some Substituted 1-Benzyl-3,4-dihydroisoquinolines. Mechanism of Enamine Photo-oxygenation
  作者：Ned H. Martin、Charles W. Jefford

  DOI：10.1002/hlca.19820650314

  日期：1982.5.5

  Bischler-Napieralski cyclization is described. Competitive methylene blue sensitized photo-oxygenation experiments allowed the determination of relative rates of photo-oxygenation of 1-benzyl-3,4-dihydroisoquinolines, Substituents were shown to affect both the equilibrium concentration of the tautomeric enamine and the overall photo-oxygenation rate. After correcting for differences in enamine concentration, the relative

  描述了通过Bischler-Napieralski环化合成一系列取代的1-苄基-3,4-二氢异喹啉。竞争性的亚甲基蓝敏化光氧合实验可确定1-苄基-3,4-二氢异喹啉的光氧合相对速率，已证明取代基会影响互变异构烯胺的平衡浓度和总光氧合速率。在校正了烯胺浓度的差异之后，相对速率数据提供了反应机理的诊断探针，该机理涉及限速步骤中电荷的转移。
• Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
  申请人：Aissaoui Hamed

  公开号：US20060178515A1

  公开（公告）日：2006-08-10

  The invention relates to novel acetamide derivatives of formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.

  本发明涉及一种新的醋酰胺衍生物（I式），以及它们作为制备药物组成部分的活性成分的用途。本发明还涉及相关方面，包括制备这些化合物的过程，含有这些化合物中的一种或多种的药物组成物，特别是它们作为促进睡眠的药物组成物中的使用，其中它们作为促进睡眠的药物组成物的奥力昔康受体拮抗剂。
• Synthesis and Identification of Small Molecules that Potently Induce Apoptosis in Melanoma Cells through G1 Cell Cycle Arrest
  作者：Robin S. Dothager、Karson S. Putt、Brittany J. Allen、Benjamin J. Leslie、Vitaliy Nesterenko、Paul J. Hergenrother

  DOI：10.1021/ja042913p

  日期：2005.6.1

  Late-stage malignant melanoma is a cancer that is refractory to current chemotherapeutic treatments. The average survival time for patients with such a diagnosis is 6 months. In general, the vast majority of anticancer drugs operate through induction of cell cycle arrest and cell death in either the DNA synthesis (S) or mitosis (M) phase of the cell cycle. Unfortunately, the same mechanisms that melanocytes possess to protect cells from DNA damage often confer resistance to drugs that derive their toxicity from S or M phase arrest. Described herein is the synthesis of a combinatorial library of potential proapoptotic agents and the subsequent identification of a class of small molecules (triphenyl methylamides, TPMAs) that arrest the growth of melanoma cells in the G1 phase of the cell cycle. Several of these TPMAs are quite potent inducers of apoptotic death in melanoma cell lines (IC50 similar to 0.5 mu M), and importantly, some TPMAs are comparatively nontoxic to normal cells isolated from the bone marrow of healthy donors. Furthermore, the TPMAs were found to dramatically reduce the level of active nuclear factor kappa-B (NF kappa B) in the cell; NF kappa B is known to be constitutively active in melanoma, and this activity is critical for the proliferation of melanoma cells and their evasion of apoptosis. Compounds that reduce the level of NF kappa B and arrest cells in the G1 phase of the cell cycle can provide insights into the biology of melanoma and may be effective antimelanoma agents.